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Abstract
Background: Despite numerous studies aimed at verifying the antitumor activity of nitric oxide-
releasing nonsteroidal antiflammatory drugs (NO-NSAIDs), little is known about the molecular
targets responsible for their antineoplastic properties. In the present study, we investigated the
mechanisms underlying the cytotoxicity of NCX 4040, a novel NO-aspirin with promising
antineoplastic action, in in vitro human colon cancer models.
Methods: The effect on tumor growth was evaluated in four human colon cancer cell lines (LoVo,
LRWZ, WiDr and LoVo Dx) by sulforhodamine B assay, oxidative stress by
immunohistochemistry, apoptosis by laddering assay, mitochondrial membrane potential (∆Ψm) by
flow cytometry, and apoptosis- and chemoresistance-related markers by western-blot and real-
time method, respectively. Prostaglandin E2 levels were determined by ELISA.
Results: NCX 4040 produced a higher cytotoxic effect in all the cell lines than that produced by
other NO donors tested. In particular, in LoVo and LRWZ cells, NCX 4040 induced a cytocidal
effect and apoptosis through p53 and NAG-1 expression, an early ∆Ψm collapse, and a sequential
release of cytoplasmatic cytochrome c and caspase -9 and -3 active forms. 8-hydroxyguanine
lesions, indicative of oxidative stress, were also observed. Conversely, in WiDr line, the drug
caused a cytocidal effect, albeit not through apoptosis, and a concomitant increase in COX-2
activity. In LoVo Dx line, characterized by high levels drug resistance and DNA repair-related
markers, only a cytostatic effect was observed, again in concomitance with the increase in COX-2
enzyme activity.
Conclusion:  This study highlights the multiplicity of mechanisms involved in sensitivity or
resistance to NCX 4040 and could provide useful indications for tailored therapy by identifying
potentially drug-responsive tumors.
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Background
Nitric oxide-releasing non-steroidal anti-inflammatory
drugs (NO-NSAIDS), which consist of a traditional
NSAID linked to an -NO2 moiety via a molecular spacer,
represent a promising class of compounds. These drugs
were developed to overcome gastrointestinal and renal
toxicities, the main limitations in the long-term use of tra-
ditional NSAIDs as chemoprotective agents against colon
cancer. The rationale behind NO-NSAID development
was based on the protective properties of nitric oxide on
the gastric mucosa, similar to that exerted by prostagland-
ins, whose biosynthesis is inhibited by traditional
NSAIDs.
Emerging data indicate that these compounds, in addition
to maintaining the chemopreventive properties of tradi-
tional NSAIDs, show enhanced safety and efficacy [1-3].
Furthermore, recent studies by our group [4,5] and by
other researchers [6] have shown that the NO-aspirin
derivative, NCX 4040, inhibits tumor cell growth and
induces apoptosis in both in vitro and in vivo experimental
systems. The efficacy of this compound seems to be inde-
pendent of tumor histotypes [7,8].
For many years the anti-tumorigenic activity of NSAIDs
was ascribed to the inhibition of cyclooxygenase (COX)
enzymes, in particular, the inducible isoform COX-2.
However, in a previous study [4] we showed the inability
of NCX 4040 to induce apoptosis in cells with high COX-
2 expression, and there is increasing evidence to suggest
that NSAIDs may also have a non COX-mediated effect
[9]. In the present study we explored other pathways of
apoptosis induction and, in particular, investigated the
role of the so-called NSAID-activated gene, NAG-1, which
belongs to the TGF-β superfamily and is characterized by
pro-apoptotic and anti-tumorigenic activities [10,11], in a
panel of human colon cancer cell lines.
Methods
Cell lines
The study was performed on four cell lines: LoVo and
WiDr, obtained from the American Type Culture Collec-
tion (Rockville, MD), LRWZ, isolated in our laboratory
from a human colon adenocarcinoma, and the multidrug-
resistant LoVo Dx, derived from LoVo cells, and kindly
provided by Dr. Mario Colombo (Istituto Nazionale
Tumori, Milan, Italy). Tumor colon cell lines were main-
tained as a monolayer at 37°C and subcultured weekly.
Culture medium was composed of DMEM/HAM F12
(1:1) supplemented with fetal calf serum (10%),
glutamine (2 mM), non-essential aminoacids (1%) (Mas-
cia Brunelli s.p.a., Milan, Italy), and insulin (10 µg/ml)
(Sigma Aldrich, Milan, Italy). Cells were used in the expo-
nential growth phase in all the experiments.
Drugs
Sodium-nitroprusside dehydrate (SNP), S-nitroso-N-
acetylpenicillamine (SNAP), diethylamine-NONOate
(NONOATE), NS-398, the selective cyclooxygenase-2
(COX-2) inhibitor (Sigma Aldrich) and NO-aspirin (NCX
4040) (NicOx SA, Sophia Antipolis, France) (Fig. 1) were
solubilized in DMSO (Carlo Erba, Milan, Italy) at a con-
centration of 50 mM, divided into aliquots and stored at -
70°C. Drug stocks were freshly diluted in culture medium
before each experiment. The final DMSO concentration
never exceeded 1% and this condition was used as control
in all the experiments.
In vitro chemosensitivity assay
SRB (sulforhodamine B) assay was used according to Ske-
han et al.'s method [12]. Briefly, cells were collected by
trypsinization, counted and plated at a density of 10,000
cells/well in 96-well flat-bottomed microtiter plates (100
µl of cell suspension per well). Experiments were run in
octuplet, and each experiment was repeated three times.
The optical density of treated cells was determined at a
wavelength of 540 nm using a fluorescence plate reader.
In the chemosensitivity assay, NCX 4040 and NO donors
were tested at scalar concentrations ranging from 1 to 50
µM for 24 hours followed by a 24-hour drug wash-out.
Growth inhibition and cytocidal effect of drugs were cal-
culated according to the formula reported by Monks [13]:
[(ODtreated - ODzero)/(ODcontrol - ODzero)] × 100%, when
ODtreated was > to ODzero. In case ODtreated was below
Chemical structure of NCX 4040 Figure 1
Chemical structure of NCX 4040.Journal of Translational Medicine 2007, 5:52 http://www.translational-medicine.com/content/5/1/52
Page 3 of 11
(page number not for citation purposes)
ODzero, cell killing had occurred. The ODzero depicts the
cell number at the moment of drug addition, the ODcontrol
reflects the cell number of untreated wells and the
ODtreated reflects the cell number in treated wells on the
day of the assay.
Mitochondrial membrane depolarization analysis
After different exposure times to NCX 4040 tested at a
concentration of 10 µM in LoVo and 50 µM in LRWZ
lines, cells were harvested, washed once in PBS and then
immediately incubated in JC-1 Working solution (BD
Biosciences Pharmingen, San Diego, CA) for 10 minutes
in a humidified atmosphere at 37°C in the dark. Cells
were then washed and resuspended in 1X Assay Buffer
(BD Biosciences Pharmingen) and analyzed (FACS Van-
tage, Becton Dickinson, San Jose, CA). Data acquisition
and analysis were performed using CELLQuest software
(Becton Dickinson). For each sample, 15,000 events were
recorded
Laddering assay
After different exposure times to NCX 4040 tested at a
concentration of 10 µM in LoVo and 50 µM in LRWZ
lines, the cells were harvested by trypsinization and their
DNA content was isolated using GenElute™ Mammalian
Genomic DNA Miniprep Kit (Sigma Aldrich), according
to the manufacturer's instructions. The DNA samples were
loaded on 1.5 % agarose gel and run at 70 mV for about 1
hour. Internucleosomal DNA fragments were visualized
by ethidium bromide under UV light.
Fluorescence microscopy analysis
Cell-permeable DNA dye 4',6-DAPI and a fluorescence
photomicroscope (Zeiss, Axioscope 40) were used to vis-
ualize chromatin condensation and/or fragmentation typ-
ical of apoptotic cells.
TUNEL assay
The percentage of apoptotic cells was evaluated by flow
cytometric analysis, according to the previously described
TUNEL assay procedure [14], in WiDr and LoVo Dx cell
lines after exposure to NCX 4040 (10 µM), to the selective
COX-2 inhibitor NS 398 (50 µM), or to both drugs.
Briefly, after treatment, cells were trypsinized, fixed,
exposed to the TUNEL reaction mixture, counterstained
with propidium iodide, and then analyzed by FACS.
Mitochondrial and cytoplasmic fractionations
The ApoAlert Cell Fractionation Kit supplied by BD Bio-
science Clontech (Palo Alto, CA) was used according to
the manufacturer's instructions, as previously described
[8]. Briefly, cells were centrifuged at 600 × g for 5 minutes
at 4°C and resuspended in 800 µl of fractionation buffer
(BD Bioscience Clontech). Cells were passed 20 times
through a 22-gauge needle and the homogenates were
centrifuged at 700 × g for 10 minutes and at 10,000 × g for
25 minutes at 4°C.
Western blot analysis
Cells were treated according to the previously described
Western blot procedure [14]. Antibodies used were anti-
caspase-3 (polyclonal antibody, Cell Signaling Technol-
ogy Inc., Beverly, MA, dilution 1:500); anti-caspase-9
(polyclonal antibody, Cell Signaling Technology Inc.,
dilution 1:500); anti-NAG-1/PTGF-β (polyclonal anti-
body, Upstate Biotechnology Inc., Lake Placid, NY, dilu-
tion 1:500); anti-p53 (PAb 1801, monoclonal antibody,
Bioptica, Milan, Italy, dilution 1:400); anti-cytochrome c
(ApoAlert Cell Fractionation Kit, BD Bioscience Clontech,
dilution 1:100), and anti-COX 4 antibody (BD Bioscience
Clontech, dilution 1:500).
The bound antibody was detected by enhanced chemilu-
minescence (ECL) using an ECL kit (Amersham Pharma-
cia Biotech, Cologno Monzese, Italy).
Oxidative damage determination
After a 6-hour exposure of LoVo to 10 µM of NCX 4040 or
a 14-hour exposure of LRWZ to 50 µM of NCX 4040, cells
were trypsinized and washed in PBS. Approximately 0.5-1
× 105 cells were plated onto microscope slides using a Cyt-
ospin cell preparation system (Shandon, Pittsburgh, PA).
Fixed samples, either untreated or treated with NCX 4040,
were stained with hematoxylin-eosin and exposed to the
antibody that specifically recognizes the presence of 8-
hydroxyguanine lesions (anti-8-oxo-dG monoclonal anti-
body, Trevigen Inc., MD, dilution 1:1000), which are
almost exclusively elicited by oxidative stress.
Prostaglandin E2 determination
The determination of prostaglandin E2 (PGE2) in culture
medium was performed using High Sensitivity Prostag-
landin E2 Enzyme Immunoassay Kit (Assay Designs, Inc.,
Ann Arbor, MI), according to the manufacturer's instruc-
tions.
mRNA RT-PCR analysis
Total cellular RNA was isolated using RNeasy Minikit
(Qiagen, Hilden, Germany). One microgram of RNA was
reverse-transcribed into cDNA using iScript (BioRad, Her-
cules, CA), according to the manufacturer's instructions,
and analyzed by real-time RT-PCR (MyiQ System, Bio-
Rad) to detect the expression of human breast cancer-
resistance protein (BCRP-1), excision repair cross-comple-
menting 1 and 2 (ERCC1-2), topoisomerase I (TOPO I),
and thymidylate synthase (TYMS) chemosensitivity mark-
ers.
The standard reaction volume was 25 µl and contained 1×
SYBR GREEN SuperMix (BioRad), 200 mM of each primerJournal of Translational Medicine 2007, 5:52 http://www.translational-medicine.com/content/5/1/52
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and 2 ul of cDNA template. The mixture was subjected to
the following cycling: 95°C for 3 minutes followed by 40
cycles of denaturation at 95°C for 15 seconds, and
annealing and extension at 60°C for 30 seconds. Primer
sequences were as follows: forward primer, 5'-ACCAAC-
CCTGACGACAGAAGAATC-3' and reverse primer, 5'-
GGCGATGTTGAAAGGCACACC-3' for TYMS; forward
primer, 5'-AGTCCAAGCATAGCAACAGTGAAC-3' and
reverse primer, 5'-CCATCTTTGTGTTTGGTCTTCTCC -3'
for TOPO 1; forward primer, 5'-TCAGTCAACAAAACG-
GACAGTCAG-3' and reverse primer, 5'-TCCTTGGGT-
TCTTTCCCAGAGC-3' for ERCC1v1; forward primer, 5'-
TCATCGCCGCATCAAGAGAAG-3' and reverse primer, 5'-
TCATCAGGGTACTTTCAAGAAGGG-3' for ERCC1v2; for-
ward primer, 5'-ATGCTTGGTGGTCTTGTTAAGTGG -3'
and reverse primer, 5'-AAGGCTCAGGATCTCAGGATGC-
3' for BCRP-1.
The amount of mRNA of each marker was normalized to
the endogenous reference β2-microglobulin using Gene
Expression Macro Software, Version 1.1 (BioRad).
Statistical analysis
The experimental values of PGE2  determination and
mRNA RT-PCR analysis represent the median from three
independent experiments. Student's t test for paired sam-
ples was performed. Differences were considered signifi-
cant at p values < 0.05 (two-sided).
Results
Cell sensitivity to NO-donors and to NCX 4040
The effect of NCX 4040 on cell growth was compared with
that of other NO donors such as, NONOATE, SNP, and
SNAP. After a 24-hour exposure to different drug concen-
trations followed by a 24-hour wash-out, NCX 4040 pro-
duced both cytostatic and cytocidal effects as a function of
the different concentrations tested in three cell lines and
only a cytostatic effect in the multidrug-resistant line LoVo
Dx, while the other NO donors generated a modest cyto-
static effect, failing to reach even IG50values (Fig. 2).
Pro-apoptotic activity of NCX 4040
As the cytotoxic effect of NCX 4040 was obtained through
apoptosis in LoVo and in LRWZ cells but not in the other
Activity of different NO donors Figure 2
Activity of different NO donors. all the cancer cell lines were exposed for 24 hours to NCX 4040 ■ , NONOATE , SNP 
▲ , SNAP O, at concentrations of 1, 5, 10 and 50 µM, followed by a 24-hour wash-out. Growth inhibition and cytocidal effect 
of drugs were calculated according to Monks' formula, as reported in Materials and methods. Each point indicates the mean of 
at least three experiments; SD never exceeded 5%.Journal of Translational Medicine 2007, 5:52 http://www.translational-medicine.com/content/5/1/52
Page 5 of 11
(page number not for citation purposes)
two lines, we investigated apoptosis mechanisms in LoVo
and LRWZ cells at 10- and 50-µM concentrations of NCX
4040, respectively, which represent the minimal drug con-
centrations capable of causing cell death in these cells
lines. Morphological analysis highlighted apoptosis with
marked chromatin condensation and/or fragmentation
(Fig. 3B-E). Furthermore, the laddering assay showed an
induction of apoptosis, which was already detectable after
only a 2-hour drug exposure (Fig. 3C-F).
Apoptosis-related events
In parallel, the presence of cells with collapse of mito-
chondrial membrane potential (∆Ψm) was observed in
both cell lines. Already present after a 2-hour exposure to
NCX 4040, it increased to more than 50% after 6 hours in
LoVo and 10 hours in LRWZ cells (Fig. 4). Moreover, in
LoVo cells, exposure to NCX 4040 induced an increased
expression of both pro-apoptotic protein p53 and NAG-1,
starting from a 2-hour and 4-hour drug exposure, respec-
tively, whereas in LRWZ, p53 expression was unaffected
and NAG-1 expression was induced after an exposure of 8
Fluorescence microscope images (A, B, D and E) Figure 3
Fluorescence microscope images (A, B, D and E). Untreated and apoptotic cells in LoVo (A, B) and LRWZ 
(D,E) cells, respectively, after a 24-hour exposure to 10 µM and 50 µM of NCX 4040, respectively, as evidenced by DAPI 
staining. Electrophoresis of genomic DNA samples (C, F). Genomic DNA isolated from LoVo (C) and LRWZ (F) cells 
after different exposure times to NCX 4040 was electrophoresed on 1.5 % agarose gel to detect internucleosomal DNA frag-
mentation. (C) (10-µM concentration of NCX 4040): lane a, untreated; lane b, 2-hour exposure; lane c, 4-hour exposure; lane 
d, 6-hour exposure; lane e, 24-hour exposure. (F) (50-µM concentration of NCX 4040): lane a, untreated; lane b, 2-hour expo-
sure; lane c, 4-hour exposure; lane d, 8-hour exposure; lane e, 16-hour exposure; lane f, 24-hour exposure; lane g, 48-hour 
exposure.Journal of Translational Medicine 2007, 5:52 http://www.translational-medicine.com/content/5/1/52
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hours and was still detectable after 48 hours (Fig. 5A and
5B).
Following pro-apoptotic protein induction and ∆Ψm col-
lapse, the release of cytoplasmatic cytochrome c and the
presence of caspase-9 and -3 active forms were observed
after a 6-hour exposure in LoVo and a 14-hour exposure
in LRWZ cells (Fig. 5C and 5D).
Furthermore, the presence of 8-hydroxyguanine lesions in
DNA was analyzed as an index of oxidative stress, which
is a potential trigger of cell death machinery. A strong
nuclear reaction to the antibody that specifically recog-
nizes the oxided nucleotides was observed in apoptotic
and non-apoptotic cells in both cell lines (Fig. 6).
Apoptosis-resistance factors
For WiDr and LoVo Dx cell lines in which a cytostatic and
cytocidal activity or only cytostatic effect was observed,
albeit not through apoptosis, we investigated mechanisms
potentially responsible for the inability of the drug to
induce programed cell death. Among these, the role of
COX-2 enzyme and its catalytic activity was evaluated as
an expression of PGE2 produced by the cyclooxygenase
enzyme after exposure to NCX 4040, to the selective COX-
2 inhibitor, NS-398, or to both drugs. As expected, NS-
398 significantly inhibited PGE2 production in both cell
lines when used singly or in combination with NCX 4040.
Conversely, NCX 4040 induced a significant increase in
prostaglandin levels in both LoVo Dx (from 160 pg/ml to
265 pg/ml) and WiDr (from 5 pg/ml to 31 pg/ml) cell
Analysis of mitochondrial membrane potential (∆Ψm) depolarization Figure 4
Analysis of mitochondrial membrane potential (∆Ψm) depolarization. After different exposure times, variations in 
∆Ψm induced by 10 µM of NCX 4040 in LoVo and 50 µM in LRWZ were detected using cationic dye JC-1 and flow cytometric 
analysis. JC-1 exhibits potential-dependent accumulation in mitochondria, as indicated by a fluorescence emission shift from 
green to red. ∆Ψm depolarization is indicated by a decrease in the red/green fluorescence intensity ratio, which is dependent 
only on the membrane potential and not on other factors such as mitochondrial size, shape or density. FL2-H, median red flu-
orescence intensity; h, hour.Journal of Translational Medicine 2007, 5:52 http://www.translational-medicine.com/content/5/1/52
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lines (Fig. 7A). Moreover, induction of apoptosis (76 % in
WiDr, 74 % in LoVo Dx) was observed after inactivation
of COX-2 enzyme by NS 398 followed by exposure to
NCX 4040 (Fig. 7B).
Furthermore, the analysis of chemoresistance- and DNA
repair-related markers showed a lower basal expression in
LoVo cells than in the corresponding doxorubicin-resist-
ant cell line (Fig. 8). In particular, expression of BCRP-1,
TYMS, ERCC1-2, and TOPO I was more than 9000-, 130-
, 30- and 30-fold higher, respectively, in LoVo Dx cells
than in the LoVo parental line.
Discussion
NSAIDs, which have long been used for pain relief, fever,
and inflammation, are currently under intense investiga-
tion to determine the extent and nature of their anti-can-
cer properties. There is mounting evidence to suggest that
the new chemical entities, NO-NSAIDs, show enhanced
anticancer activity compared to native NSAIDs. We
recently demonstrated that NCX 4040 is highly effective
in inhibiting the growth of human colon cancer cells in
vitro through apoptotic pathways in two of the four cell
lines investigated [4]. In the present work, we showed that
apoptosis occurs mainly via the mitochondrial pathway,
with early mitochondrial membrane depolarization fol-
Protein expression of apoptotic markers Figure 5
Protein expression of apoptotic markers. (A) p53 and NAG-1 protein expression in LoVo cells after different exposure 
times to NCX 4040. (B) NAG-1 protein expression in LRWZ cells after different exposure times to NCX 4040. (C) Cyto-
chrome c, caspase-9 and -3 protein expression in LoVo cells: lane a, untreated; lane b, 6-hour NCX 4040 exposure (10 µM). 
(D) Cytochrome c, caspase-9 and -3 protein expression in LRWZ cells: lane a, untreated; lane b, 14-hour NCX 4040 exposure 
(50 µM).Journal of Translational Medicine 2007, 5:52 http://www.translational-medicine.com/content/5/1/52
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lowed by cytochrome c release into the cytoplasm and cas-
pase-9 and -3 activation. This is in agreement with results
previously reported by our group for other tumor histo-
types [7,8]. Furthermore, the different susceptibility of the
various colon cancer cell lines to apoptosis makes this
experimental system an interesting model to improve our
understanding of the molecular mechanisms that are
determinants in triggering cell death.
In the two cell lines prone to apoptosis, we observed the
induction of the specific NSAID-activated gene (NAG-1)
after a short exposure to NCX 4040, highlighting the role
of the aspirin component in the pro-apoptotic activity of
the NO-derivative. NAG-1 is a divergent member of the
transforming growth factor-β superfamily. Several studies
have shown that the anti-tumorigenic and pro-apoptotic
role of NAG-1 protein [11,15,16] is regulated by several
NSAIDs, such as aspirin, indomethacin and ibuprofen,
providing new clues to explain the anti-cancer activities of
these anti-inflammatory agents.
The NAG-1 promoter has been characterized and many
transcription factors, including p53 [17], are known to
regulate this gene. However, the original finding that
NAG-1 expression is also induced by NSAIDs in p53 null
cell lines [11] seems to indicate the existence of non p53-
mediated activation mechanisms. Consistently with this
hypothesis, we observed an increment of NAG-1 expres-
sion in both LoVo and LRWZ cells and an increment of
p53 in only the former cell line.
Our group also hypothesized that the NO component of
the molecule plays a pivotal role in the cytotoxic and pro-
apoptotic activity of NCX 4040 [4,7,8]. NO is synthesized
by normal and neoplastic tissues [18,19] and it has been
shown that low endogenous NO levels increase cell prolif-
DNA oxidative damage Figure 6
DNA oxidative damage. After (A) a 6-hour exposure to 10 µM of NCX 4040 in LoVo and (B) a 14-hour exposure to 50 
µM of NCX 4040 in LRWZ, cells were exposed to the antibody that specifically recognizes the presence of nuclear 8-hydrox-
yguanine lesions, which are almost exclusively elicited by oxidative stress. Each 100× magnification shows a detail of the corre-
sponding 40× photo. All the pictures are representative of three independent experiments.Journal of Translational Medicine 2007, 5:52 http://www.translational-medicine.com/content/5/1/52
Page 9 of 11
(page number not for citation purposes)
eration, whereas high levels cause cytotoxicity and apop-
tosis [20,21]. Moreover, NO released from chemical
agents, such as SNP, and other NO-generating molecules
has shown anti-proliferative and pro-apoptotic properties
in cells from different tumor histotypes in vitro and in vivo
[22-24]. In the present study, we showed that NCX 4040
is more effective in inhibiting cancer cell proliferation
than the other three NO-donors, SNP, SNAP and NON-
OATE. The enhanced effect of NCX 4040 with respect to
the classic NO donor compounds is probably largely due
to the high -NO release capacity of the spacer component,
whose important role in the efficacy of the drug was also
highlighted in the work by Kashfi and Rigas [25]. The piv-
otal role of the -NO molecule in the anti-tumor activity of
the drug was further confirmed by the detection, for the
first time, of 8-hydroxyguanine lesions, an index of oxida-
tive stress [26], in the DNA of cells that underwent apop-
tosis after a short exposure to NCX 4040.
The results of the present study also provided some poten-
tial explanations for the inability of NCX 4040 to trigger
cell death machinery in LoVo Dx and WiDr cells.
In a previous study we showed that COX-2 expression did
not change in either WiDr or LoVo Dx cell lines after NCX
4040 exposure [4]. In the present work we analyzed the
effect of drugs on the catalytic activity of the COX-2
enzyme, as expressed by PGE2 levels. As expected, a con-
siderable inhibition was observed following exposure to
NS-398, a specific inhibitor of COX-2 catalytic activity,
whereas, surprisingly, a significant increment was seen
after exposure to NCX 4040. This finding, already
reported by other authors in cancer cell lines with an ele-
vated resistance to apoptosis induced by traditional
NSAIDs [27-29] and NO-NSAIDs [30,31], together with
the observation that LoVo and LRWZ lines did not express
this cyclooxygenase isoform [4], raises intriguing ques-
tions about the biological role of COX-2 in the natural
Quantitative determination of PGE2 levels in culture medium by ELISA assay Figure 7
Quantitative determination of PGE2 levels in culture medium by ELISA assay. (A). Variations induced in WiDr and 
LoVo Dx cells by a 24-hour exposure to NS 398 (50 µM), NCX 4040 (50 µM), or both drugs. Apoptosis induction after 
inhibition of COX-2 enzyme (B). Percentage of apoptotic cells after exposure of WiDr and LRWZ cells to NS398, NCX 
4040 or both drugs.Journal of Translational Medicine 2007, 5:52 http://www.translational-medicine.com/content/5/1/52
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history of cancer and also about the mechanisms by
which NSAIDs, including NO-NSAIDs, are capable of pre-
venting cancer. Moreover, the onset of apoptosis in cell
death-resistant WiDr and LoVo Dx lines after COX-2 inhi-
bition and exposure to NCX 4040 clearly indicates the
close correlation between this enzyme and resistance to
apoptosis.
In addition to basal elevated COX-2 expression, the high
expression of chemoresistance- and DNA repair-related
markers in LoVo Dx may explain both the weak cytotoxic
effect of NCX 4040 and its failure to trigger apoptosis in
this cell line.
Conclusion
In conclusion, our results indicate that NCX 4040, a novel
NO-aspirin, exerts a different cytotoxic activity as a func-
tion of the molecular profile of human colon cancer cells.
Furthermore, the data we obtained strongly suggest that
the NO-releasing moiety (-NO2) is responsible for the
apoptotic process, which is also enhanced by the aspirin
component of the molecule, as shown by its specific
induction of the pro-apoptotic protein, NAG-1. In partic-
ular, it would seem that the cytocidal effect of NCX 4040
is obtained via mitochondrial pathway-mediated apopto-
sis in the cells not expressing the COX-2 enzyme, which,
conversely, is upregulated after drug exposure in cells fail-
ing to undergo apoptosis. These observations, together
with the finding that the most resistant cell line was char-
acterized by high levels of drug resistance and DNA repair-
related markers, highlight the multiplicity of mechanisms
involved in sensitivity or resistance to the drug and could
provide useful indications for tailored therapy by identify-
ing potentially drug-responsive tumors.
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